AbbVie to Acquire Gilgamesh's Bretisilocin Program for Up to $1.2 Billion
PorAinvest
lunes, 25 de agosto de 2025, 1:46 pm ET1 min de lectura
ABBV--
The acquisition highlights AbbVie's commitment to expanding its psychiatry pipeline. Bretisilocin, a novel, short-acting 5-HT2A receptor agonist and 5-HT releaser, has demonstrated promising results in Phase 2a trials, showing a clinically significant reduction in depressive symptom severity compared to a low-dose active comparator [1].
As part of the transaction, Gilgamesh will spin off a new entity named Gilgamesh Pharma Inc. to hold its employees and other programs, including its oral NMDA receptor antagonist blixeprodil (GM-1020), cardio-safe ibogaine analog, M1/M4 agonist program, and existing collaboration with AbbVie. This spin-off will allow Gilgamesh to focus on its broader mission of developing novel, transformative therapies for complex mental health and neurological conditions [2].
The acquisition builds upon AbbVie and Gilgamesh's 2024 collaboration and option-to-license agreement to advance the development of next-generation therapies for psychiatric disorders. This option-to-license remains in effect and will be transferred to Gilgamesh Pharma Inc. in connection with the spin-out [3].
The transaction is subject to customary closing conditions and is expected to be completed in the coming months. This deal underscores AbbVie's leadership in neuroscience and its commitment to advancing innovative treatments in psychiatry.
References:
[1] https://www.nasdaq.com/press-release/abbvie-acquire-gilgamesh-pharmaceuticals-bretisilocin-novel-investigational-therapy
[2] https://seekingalpha.com/news/4488733-abbvie-to-buy-gilgameshs-depression-program-for-up-to-12b
[3] https://www.prnewswire.com/news-releases/abbvie-to-acquire-gilgamesh-pharmaceuticals-bretisilocin-a-novel-investigational-therapy-for-major-depressive-disorder-expanding-psychiatry-pipeline-302537266.html
AbbVie has agreed to acquire Gilgamesh Pharmaceuticals' lead investigational candidate, Bretisilocin, for up to $1.2 billion. The deal includes an upfront payment plus development milestones. Bretisilocin is a serotonin receptor agonist and releaser currently in Phase 2 development for depression treatment.
AbbVie (NYSE: ABBV) has agreed to acquire Gilgamesh Pharmaceuticals' lead investigational candidate, Bretisilocin, for up to $1.2 billion. The deal includes an upfront payment plus development milestones. Bretisilocin is a serotonin receptor agonist and releaser currently in Phase 2 development for the treatment of major depressive disorder (MDD).The acquisition highlights AbbVie's commitment to expanding its psychiatry pipeline. Bretisilocin, a novel, short-acting 5-HT2A receptor agonist and 5-HT releaser, has demonstrated promising results in Phase 2a trials, showing a clinically significant reduction in depressive symptom severity compared to a low-dose active comparator [1].
As part of the transaction, Gilgamesh will spin off a new entity named Gilgamesh Pharma Inc. to hold its employees and other programs, including its oral NMDA receptor antagonist blixeprodil (GM-1020), cardio-safe ibogaine analog, M1/M4 agonist program, and existing collaboration with AbbVie. This spin-off will allow Gilgamesh to focus on its broader mission of developing novel, transformative therapies for complex mental health and neurological conditions [2].
The acquisition builds upon AbbVie and Gilgamesh's 2024 collaboration and option-to-license agreement to advance the development of next-generation therapies for psychiatric disorders. This option-to-license remains in effect and will be transferred to Gilgamesh Pharma Inc. in connection with the spin-out [3].
The transaction is subject to customary closing conditions and is expected to be completed in the coming months. This deal underscores AbbVie's leadership in neuroscience and its commitment to advancing innovative treatments in psychiatry.
References:
[1] https://www.nasdaq.com/press-release/abbvie-acquire-gilgamesh-pharmaceuticals-bretisilocin-novel-investigational-therapy
[2] https://seekingalpha.com/news/4488733-abbvie-to-buy-gilgameshs-depression-program-for-up-to-12b
[3] https://www.prnewswire.com/news-releases/abbvie-to-acquire-gilgamesh-pharmaceuticals-bretisilocin-a-novel-investigational-therapy-for-major-depressive-disorder-expanding-psychiatry-pipeline-302537266.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios